VA Healthcare System names Morgan new director

The Department of Veterans Affairs has announced Mark E. Morgan as the new director of the Eastern Oklahoma VA Health Care System. Morgan will oversee delivery of healthcare to more than 47,000 veterans and an operating budget of $250 million, reports the Tahlequah Daily Press.

“We are excited to bring Mr. Morgan on board as the new director of the Eastern Oklahoma VA Health Care System,” said Ralph T. Gigliotti, Veterans Integrated Service Network 19 director. “His sound leadership qualities and proven experience will be valuable assets for the facility, the employees and volunteers, and most importantly, for the veterans we are honored to serve. We anticipate he will arrive at the medical center within the next 45 to 60 days to begin his appointment.”

Morgan has more than 28 years of experience in healthcare administration, strategic planning, operations, logistics, human resources, compliance, safety, security and emergency management.

Morgan joined the VA 17 years ago and has held leadership positions at a number of VA facilities in the U.S. Most recently, he was the compliance and business integrity officer for South Central VA Health Care Network.

He served in many different leadership positions within the VA including acting director of the Central Arkansas Veterans Healthcare System, acting associate director of the G.V. “Sonny” Montgomery VAMC and the acting director of the Gulf Coast Veterans Health Care System.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.